March 19, 2018/by dandersonShangPharma Innovation Expands Incubator to Drive Life Science Innovation in Bay Area
January 16, 2018/by dandersonShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration
November 8, 2017/by dandersonPartners HealthCare raises $171 million to invest in early-stage life science companies
October 9, 2017/by dandersonShangPharma Innovation and SRI International Announce Drug Discovery Collaboration
July 11, 2017/by dandersonShangPharma Innovation and the University of California San Francisco Announce Strategic Research Collaboration
July 8, 2017/by dandersonThe Scripps Research Institute and ShangPharma Innovation Announce Translational Research Collaboration
May 24, 2017/by dandersonShangPharma Innovation Appoints Mohamad Moghadam-Tabrizi as Senior Vice President of Business Development
March 17, 2020/by shawnShangPharma Innovation portfolio company Circle Pharma raises $45 Million in Series B Financing
November 18, 2019/by shawnShangPharma Innovation portfolio company Rodin Therapeutics acquired by Alkermes for up to $950 million
November 6, 2019/by shawnArtios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
June 12, 2019/by shawnShangPharma Innovation portfolio company Tilos Therapeutics acquired for up to $773 Million by Merck
January 24, 2018/by dandersonEndpoints: When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse?
January 16, 2018/by dandersonEndpoints: AveXis wants $400M more for promising SMA gene therapy; ShangPharma partners with Icahn School of Medicine at Mount Sinai
January 16, 2018/by dandersonNew York Business Journal: ShangPharma Innovation partners with Icahn School of Medicine
January 16, 2018/by dandersonBioSpace: ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration
November 6, 2019/by shawnArtios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
June 12, 2019/by shawnShangPharma Innovation portfolio company Tilos Therapeutics acquired for up to $773 Million by Merck
January 24, 2018/by dandersonEndpoints: When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse?
January 16, 2018/by dandersonEndpoints: AveXis wants $400M more for promising SMA gene therapy; ShangPharma partners with Icahn School of Medicine at Mount Sinai
January 16, 2018/by dandersonNew York Business Journal: ShangPharma Innovation partners with Icahn School of Medicine
January 16, 2018/by dandersonBioSpace: ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration
March 17, 2020/by shawnShangPharma Innovation portfolio company Circle Pharma raises $45 Million in Series B Financing
November 18, 2019/by shawnShangPharma Innovation portfolio company Rodin Therapeutics acquired by Alkermes for up to $950 million
November 6, 2019/by shawnArtios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
